- Patients with metastatic NSCLC treated with first-line chemotherapy who received allogeneic blood transfusion (ABT) before or during therapy had significantly worse outcomes than those who received no transfusion.
- Effect was pronounced with adenocarcinoma histology.
Why this matters
- Blood transfusions may cause immunosuppression and have been shown to negatively affect outcomes in some cancers, including early-stage lung cancer.
- 433 patients with metastatic NSCLC receiving first-line chemotherapy received ABT before treatment (n=43), during treatment (n=87), or not at all (n=303).
- Funding: None.
- Median PFS was significantly better with no-ABT than with ABT before or during treatment (7.0 vs 5.0 vs 4.0 months, respectively; P<.001>
- Median OS was also significantly better with no-ABT than with ABT before or during treatment (14.0 vs 9.0 vs 7.0 months, respectively; P<.001>
- In adenocarcinoma patients, median PFS and OS were better in patients with no-ABT than with ABT before or during treatment (8.0 vs 3.0 vs 3.0 months [P<.001 and vs months respectively>
- Receiving ABT during treatment was associated with worse PFS (aHR, 1.506; P=.003) and worse OS (aHR, 1.369; P=.025).
- Retrospective, single-center study.